Continued improvement through week 12 with no plateau. In contrast, placebo-treated patients showed minimal improvement that plateaued early. FDA approval guidance (2020) supports the use of responder ...

Study Designed to Evaluate the Safety, Tolerability, and Efficacy with PL8177 Oral Colon Delivery in Adult Subjects with Active Ulcerative Colitis Oral PL8177 May Provide a Safe and Tolerable ...

Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin's focus is solely on its development and clinical pipeline based on the melanocortin receptor system ...

~30-40% of ED patients do not respond to PDE5i treatment Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i Successfully co-formulated ...

PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its shares at a ratio of 1-for-50. The Reverse ...

CRANBURY, N.J., Sept. 27, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that ...

CRANBURY, N.J., Nov. 25, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

PRINCETON, N.J., July 15, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity ...

CRANBURY, N.J. - Palatin Technologies (NYSE:PTN), Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $20.4 million, has announced its corporate milestones for 2025, ...

CRANBURY, N.J., June 28, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN) a biopharmaceutical company developing first-in-class medicines based on molecules that ...

MC4R plays a significant role in eating behavior and how our bodies manage energy. Palatin has identified the specific structural parts of a peptide that are responsible for MC1R agonism, which causes ...

CRANBURY, N.J., Nov. 14, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...